Atea Pharmaceuticals, Inc. (AVIR) Stock

Atea Pharmaceuticals, Inc. (AVIR) is a Healthcare stock trading at $4.36 (as of 2026-06-18), with a market capitalization of $336.91M and a trailing P/E of -2.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for patients with viral infections. Its pipeline includes AT-527 for COVID-19 and other antiviral candidates such as AT-752, AT-777, and AT-787, alongside AT-281 and ruzasvir for chronic hepatitis C, with a Merck license related to ruzasvir.

Valuation — source: SEC EDGAR (first-party)
Price$4.36
Market Cap$336.91M
P/E Ratio-2.1
EV / EBITDA-1.5
Price / Book1.54
DCF Value (model)$-27.01
DCF Upside vs Price-719.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$351.37M
Net Margin34.5%
Return on Equity-72.5%
Current Ratio7.89
Valuation vs Sector & Industry
Stock P/E-2.1
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-110.2%
vs Industry-112.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($64.30M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJean-Pierre Sommadossi
Employees56
CountryUS
IPO Date2020-10-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Abeona Therapeutics Inc. (ABEO)
  • Immuneering Corporation (IMRX)
  • Aardvark Therapeutics, Inc. Common Stock (AARD)
  • Protara Therapeutics, Inc. (TARA)
  • Immix Biopharma, Inc. (IMMX)
  • Inhibikase Therapeutics, Inc. (IKT)
  • Galectin Therapeutics Inc. (GALT)
  • Fennec Pharmaceuticals Inc. (FENC)
AVIR earnings history · AVIR institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.